Linagliptin

Lebitso la lik'hemik'hale:

8-[(3R)-3-aminopiperidin-1-yl]-7-(empa-2-yn-1-yl)-3- methyl-1--[(4-methylquinazolin-2-yl)methyl]-3 , 7-dihydro-1H-purine-2,6-dione

SMILES Khouto:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Khoutu ea InChi:

InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

InChi Key:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Keyword:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Sollubility:E qhibiliha ka DMSO

Polokelo:0 - 4 ° C bakeng sa nako e khutšoanyane (matsatsi ho isa libeke), kapa -20 ° C bakeng sa nako e telele (likhoeli).

Tlhaloso:

Linagliptin, eo hape e tsejoang e le BI-1356, ke inhibitor ea DPP-4 e ntlafalitsoeng ke Boehringer Ingelheim bakeng sa kalafo ea lefu la tsoekere la mofuta oa II. Linagliptin (hang ka letsatsi) e amohetsoe ke US FDA ka la 2 Motšeanong 2011 bakeng sa kalafo ea lefu la tsoekere la mofuta oa II. E ntse e rekisoa ke Boehringer Ingelheim le Lilly.

Sepheo: DPP-4